Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | GPR119 | Q8TDV5 | 13/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.45 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28634725 | 0.85 | USP30 (0.61) | ALDH1A1LMNAMAPTGPR119KMT2A | |
| SCHEMBL27214742 | 0.84 | GPR119 (0.53) | GPR119KMT2AUSP30PTPN2PTPN1 | |
| SCHEMBL166256 | 0.78 | ALDH1A1 (0.55) | ALDH1A1LMNAMAPTKMT2AHTT | |
| SCHEMBL27178727 | 0.78 | ALDH1A1 (0.60) | ALDH1A1LMNAMAPTGPR119KMT2A | |
| SCHEMBL27178869 | 0.78 | PDK2 (0.51) | ALDH1A1LMNAMAPTGPR119KMT2A | |
| SCHEMBL4736392 | 0.77 | MAPT (0.65) | ALDH1A1LMNAMAPTGPR119PTPN2 | |
| SCHEMBL6802356 | 0.77 | MAPT (0.59) | ALDH1A1LMNAMAPTGPR119KMT2A | |
| SCHEMBL6802352 | 0.77 | MAPT (0.59) | ALDH1A1LMNAMAPTGPR119KMT2A | |
| SCHEMBL111070 | 0.77 | ALDH1A1 (0.72) | ALDH1A1LMNAMAPTKMT2AHTT | |
| SCHEMBL15041117 | 0.76 | ALDH1A1 (0.52) | ALDH1A1LMNAMAPTGPR119KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4594319-A1 | BICYCLIC COMPOUNDS | Aligos Therapeutics, Inc. (US) | 2025-08-06 | — | — | EP | disclosed |
| US-20240150351-A1 | BICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. | 2024-05-09 | — | — | US | disclosed |
| WO-2024073559-A1 | BICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. (US) | 2024-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240150351-A1 | BICYCLIC COMPOUNDS | SLC10A1, PKD1, CYP11B2 | ALDH1A1 543/4885LMNA 1338/4885MAPT 1168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.